BATM Advanced Communications, a provider of real-time technologies for networking solutions and medical laboratory systems, has announced the commercial launch of its RAPiDgen SARS-CoV-2 Ag test, a rapid test that gives results in 8-15 minutes.
The test consists of a small self-contained device and a nasal swab: after collecting a nasal secretion sample, the swab is placed into an opening in the device, swirled and then the cap clicked to a different direction.
This compares with commonly available rapid tests that require the individual to prepare the test by pouring a buffer liquid into an extraction tube and, after swirling the swabbed sample in the extraction tube, dropping liquid onto a test strip.
The RAPiDgen SARS-CoV-2 Ag, which uses the lateral flow method, has undergone validation testing by hospitals in Israel and Europe where it has demonstrated sensitivity in excess of 95%.
The test has been developed by BATM’s Adaltis subsidiary in partnership with Gamidor Diagnostics, part of the Gamida for Life B.V. group.
